Pharmaceutical policies: Effects of cap and co-payment on rational use of medicines

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 5, 2015, Pages

  Luiza, Vera Lucia ^a   Chaves, Luisa A ^a   Silva, Rondineli M ^a   Emmerick, Isabel Cristina M ^b   Chaves, Gabriela C ^a   Fonseca de Araújo, Silvia Cristina ^c   Moraes, Elaine L ^d   Oxman, Andrew D ^e  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Rio de Janeiro County Health Department   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^e NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL OUTCOME; DRUG COST; DRUG USE; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; LIFE SUSTAINING TREATMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; COST; DRUG CONTROL; ECONOMICS; FEE; REIMBURSEMENT;

DRUG;

COST SHARING; DRUG AND NARCOTIC CONTROL; DRUG COSTS; FEES, PHARMACEUTICAL; INSURANCE, HEALTH, REIMBURSEMENT; PHARMACEUTICAL PREPARATIONS;

EID: 84945356780     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007017.pub2     Document Type: Review

References (199)

1. Andersson K, Petzold MG, Sonesson C, Lonnroth K, Carlsten A. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy 2006;79(2-3):231-43.
2. Blais L, Couture J, Rahme E, LeLorier J. Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance. Health Policy 2002;64:163-72.
3. Caetano PA, Raymond CB, Morgan S, Yan L. Income-based drug coverage in British Columbia: the impact on access to medicines. Health Policy 2006;2(2):e154-69.
4. Chen H, Nwangwu A, Aparasu R, Essien E, Sun S, Lee K. The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services 2008; Vol. 59, issue 10:1191-7.
5. Cromwell DM, Bass EB, Steinberg EP, Yasui Y, Racich WJ, Hendrich TR, et al. Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing hospitalizations?. Health Services Research 1999;33(6):1593-610.
6. Donnelly N, McManus P, Dudley J, Hall W. Impact of increasing the re-supply interval on seasonality of subsidised prescription use in Australia. Australian and New Zealand Journal of Public Health 2000;24(6):603-6.
7. Dormuth CR, Glynn RJ, Neumann P, Maclure M, Brookhart AM, Schneeweiss S. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clinical Therapeutics 2006;28:964-78.
8. Dormuth CR, Maclure M, Glynn RJ, Newman P, Brookhart AM, Schneeweiss S. Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications. Clinical Therapeutics 2008;30:1038-50.
9. Dormuth CR, Neumann P, Maclure M, Glyn RJ, Schneeweiss S. Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications. Medical Care 2009;47(5):508-16.
10. Hartung DM, Carlson MJ, Kraemer DF, Haxby DG, Ketchum KL, Greenlick MR. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population. Medical Care 2008;46(6):565-72.
11. Huskamp HA, Deverka PA, Landrum MB, Epstein RS, McGuigam KA. The effect of three-tier formulary adoption on medication continuation and spending among elderly retirees. Health Services Research 2007;42(5):1926-42.
12. Hux JE, Naylor CD, Fielding DA. The Ontario Drug Benefit Program Copayment: its impact on access for Ontario seniors and charges to the program. Institute for Clinical Evaluation Sciences in Ontario. Toronto, April 24, 1997:1-13.
13. Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J, et al. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiology and Drug Safety 2008;17(11):1091-9.
14. Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia. Austrialian and New Zealand Journal of Public Health 2009;33(3):246-52.
15. McManus P, Donnelly N, Henry D, Hall W, Primrose J, Lindner J. Prescription drug utilization following patient co-payment changes in Australia. Pharmacoepidemiology and Drug Safety 1996;5(6):385-92.
16. Nelson AA, Reeder CE, Dickson WM. The effect of a Medicaid drug copayment program on the utilization and cost of prescription services. Medical Care 1984;22(8):724-36.
17. Foxman B, Valdez RB, Lohr KN, Goldberg GA, Newhouse JP, Brook RH. The effect of cost sharing on the use of antibiotics in ambulatory care: results from a population-based randomized controlled trial. Journal of Chronic Disease 1987;40(5):429-37.
18. Leibowitz A. Substitution between prescribed and over-the-counter medications. Medical Care 1989;27(1):85-94.
19. Leibowitz A, Manning WG, Newhouse JP. The demand of prescription drugs as a function of cost-sharing. Social Science & Medicine 1985;21(10):1063-9.
20. Newhouse JP. Free for all? Lessons from the Rand Health Insurance Experiment. US: Harvard University Press, 1993.
21. Newhouse JP, Manning WG, Morris CN, Orr LL, Duan N, Keeler EB, et al. Some interim results from a controlled trial of cost sharing in health insurance. The New England Journal of Medicine 1981;305(25):1501-7.
22. Ong M, Catalano R, Hartig T. A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999. Clinical Therapeutics 2003;25(4):1264-75.
23. Poirier S, LeLorier J, Page V, Lacour A. The effect of a $2 co-payment on prescription refill rates of Quebec elderly and its relationship to socio-economic status. Canadian Pharmacy Journal 1998;131(1):30-4.
24. Polinski JM, Brookhart MA, Glynn RJ, Schneeweiss S. Medicare part D's impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. Journal of Clinical Psychopharmacology 2012;32:3-10.
25. Reeder CE, Nelson AA. The differential impact of copayment on drug use in a Medicaid population. Inquiry 1985;22:396-403.
26. Roblin DW, Platt R, Goodman MJ, Hsu J, Nelson WW, Smith DH, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much?. Medical Care 2005;43(10):951-9.
27. Sawyer DO. Medicaid spending and state cost control: assessing policy impact on drug expenditure. Health Policy Quarterly 1982;2(2):98-123.
28. Schneeweiss S, Patrick AR, Pedan A, Varasteh L, Levin R, Liu N, et al. Market Watch: the effect of medicare part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Affairs 2009;28(2):w305-16.
29. Shrank WH, Patrick AR, Pedan A, Polinski JM, Varasteh L, Levin R, et al. The effect of transitioning to medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. Journal of the American Geriatric Society 2008;56(12):2304-10.
30. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. New England Journal of Medicine 1987;317(9):550-6.
31. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.[comment]. New England Journal of Medicine 1991;325(15):1072-7.
32. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 1994;331(10):650-5.
33. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons [comment]. JAMA 2001;285(4):421-9.
34. Wang PS, Patrick AR, Dormuth CR, Avorn J, Maclure M, Canning CF, et al. The impact of cost sharing on antidepressant use among older adults in British Columbia. Psychiatric Services 2008;59(4):377-83.
35. Yin W, Basu A, Zhang JX, Rabbani A, Meltzer DO, Alexander GC. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Annals of Internal Medicine 2008;148(3):169-77.
36. Zhang Y, Lave JR, Newhouse JP, Donohue JM. How the Medicare part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries. Journals of Gerontology Series B: Psychological Sciences and Social Sciences 2009;65B(4):502-7.
37. Anis AH, Guh DP, Lacaille D, Marra CA, Rashidi AA, Li X, et al. When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions. Canadian Medical Association Journal November 22, 2005;173(11):1335-40.
38. Balkrishnan R, Byerly WG, Camacho FT, Shrestha A, Anderson RT. Effect of prescription benefit changes on medical care utilization in a Medicare HMO population. The American Journal of Managed Care November 2001;7(11):1093-100.
39. Basu A, Yin W, Alexander GC. The impact of Medicare part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Services Research 2008;45(1):133-51.
40. Bazalo G, Weiss RC. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing. Consultant Pharmacist April 2012;27(4):269-73.
41. Bishop CE, Ryan AM, Gilden DM, Kubisiak J, Thomas CP. Effect of an expenditure cap on low-income seniors' drug use and spending in a state pharmacy assistance program. Health Services Research 2009;44(3):1010-28.
42. Bloom JR, Cheng JS, Hu TW, Kang SH, Wallace N. Use of antipsychotic medications in treating schizophrenia among different financing and delivery systems. Journal of Mental Health Policy and Economics 2003;6(4):163-71.
43. Brian EW, Gibbens SF. California's Medi-Cal copayment experiment. Medical Care 1974;12(12):1-303.
44. Chang KC. Implementation of 3-tier plan design and employee education slows drug spend. Drug Benefit Trends 2005;17(4):162-71.
45. Colby MS, Esposito D, Goldfarb S, Ball DE, Herrera V, Conwell LJ, et al. Medication discontinuation and reinitiation among Medicare part D beneficiaries taking costly medications. American Journal of Pharmacy Benefits 2011;3(5):e102-10.
46. Cox ER, Jernigan C, Coons SJ, Draugalis JL. Medicare beneficiaries' management of capped prescription benefits. Medical Care 2001;39(3):296-301.
47. Crane MM, Manson S, Juneja M, Allen J, Kurrasch RH, Chu ME, et al. Direct costs in newly diagnosed and established rheumatoid arthritis patients, and comparison with non-rheumatoid arthritis controls in an insurance claims database. [abstract]. Arthritis and Rheumatism 2011; Vol. 63, issue Suppl 10:916.
48. Crown WH, Berndt ER, Baser O, Finkelstein SN, Witt WP, Maguire J, et al. Benefit plan design and prescription drug utilization among asthmatics: do patient copayments matter?. Frontiers in Health Policy Research 2004;7:95-127.
49. Dhippayom T, Walker R. Impact of the reduction of the prescription charge in Wales on the prescribing of non-sedating antihistamines in primary care. Health Policy 2008;87(3):309-15.
50. Donohue JM, Zhang Y, Lave JR, Gellad WF, Men A, Perera S, et al. The Medicare drug benefit (Part D) and treatment of heart failure in older adults. American Heart Journal 2010;160(1):159-65.
51. Donohue JM, Marcum ZA, Gellad WF, Lave JR, Men A, Hanlon JT. Medicare Part D and potentially inappropriate medication use in the elderly. American Journal of Managed Care 2012;18(9):e315-22.
52. Farley JF. Medicaid prescription cost containment and schizophrenia: a retrospective examination. Medical Care 2010;48(5):440-7.
53. Farley JF. Medicaid prescription cost containment and schizophrenia: a retrospective examination. Medical Care 2010;48(5):440-7.
54. Fu AZ, Tang AS, Wang N, Du DT, Jiang JZ. Effect of Medicare part D on potentially inappropriate medication use by older adults. Journal of the American Geriatrics Society 2010;58(5):944-9.
55. Fung V, Mangione CM, Huang J, Turk N, Quiter ES, Schmittdiel JA, et al. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes. Health Services Research 2010;45(2):355-75.
56. Gibson TB, McLaughlin CG, Smith DG. A copayment increase for prescription drugs: the long-term and short-term effects on use and expenditures. Inquiry 2005;42(3):293-310.
57. Gibson TB, Jing Y, Bagalman JE, Cao Z, Bates JA, Hebden T, et al. Impact of cost-sharing on treatment augmentation in patients with depression. American Journal of Managed Care 2012;18(1):e15-22.
58. Goedken AM, Urmie JM, Farris KB, Doucette WR. Effect of cost sharing on prescription drug use by Medicare beneficiaries prior to the Medicare Drug Benefit and potential adverse selection in the benefit. Journal of the American Pharmaceutical Association 2009;49(1):18-25.
59. Goisis G, Parravicini P. Drug expenditure and cost sharing: a new (age-old) controversy. RISEC: International Review of Economics and Business 2002;49(3):349-66.
60. Gu Q, Zeng F, Patel BV, Tripoli LC. Part D coverage gap and adherence to diabetes medications. The American Journal of Managed Care 2010;16(2):911-8.
61. Harris BL, Stergachis A, Ried LD. The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Medical Care 1990;28(10):907-17.
62. Holloway KA, Gautam BR, Reeves BC. The effects of different kinds of user fees on prescribing quality in rural Nepal. Journal of Clinical Epidemiology 2001;54(10):1065-71.
63. Holmes HM, Luo R, Hanlon JT, Elting LS, Suarez-Almazor M, Goodwin JS. Ethnic disparities in adherence to antihypertensive medications of medicare part D beneficiaries. Journal of the American Geriatrics Society 2012;60(7):1298-303.
64. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Muriel AC, et al. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Archives of General Psychiatry 2005;62(4):435-41.
65. Johnston SS, Juday T, Seekins D, Espindle D, Chu BC. Association between prescription cost sharing and adherence to initial combination antiretroviral therapy in commercially insured antiretroviral-naïve patients with HIV. Journal of Managed Care Pharmacy 2012;18(2):129-45.
66. Kephart G, Skedgel C, Sketris I, Grootendorst P, Hoar J. Effect of copayments on drug use in the presence of annual payment limits. American Journal of Managed Care 2007;13(6 Pt 2):328-34.
67. Ketcham JD, Simon KI. Medicare Part D's effects on elderly patients' drug costs and utilization. American Journal of Managed Care 2008;14(11 Suppl):SP14-22.
68. Kim YA, Rascati KL, Prasla K, Godley P, Goel N, Dunlop D. Retrospective evaluation of the impact of copayment increases for specialty medications on adherence and persistence in an integrated health maintenance organization system. Clinical Therapeutics 2011;33(5):598-607.
69. Klepser DG, Huether JR, Handke LJ, Williams CE. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance. Journal of Managed Care Pharmacy 2007;13(9):765-77.
70. Kozyrskyj A, Mustard C, Cheang M, Simons F. Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma. Canadian Medical Association Journal 2001;165(7):897.
71. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. American Journal of Managed Care 2005;11(10):621-8.
72. Li P, McElligott S, Bergquist H, Schwartz JS, Doshi JA. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia. Annals of Internal Medicine 2012;156(11):776-84.
73. Lingle EW Jr, Kirk KW, Kelly WR. The impact of outpatient drug benefits on the use and costs of health care services for the elderly. Inquiry 1987;24(3):203-11.
74. Liu SZ, Romeis JC. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly. Medical Care 2003;41(12):1331-42.
75. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Affairs (Millwood) 2010;29(11):2002-8.
76. Maciejewski ML, Bryson CL, Perkins M, Blough DK, Cunningham FE, Fortney JC, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. American Journal of Managed Care 2010;16(1):e20-34.
77. Marshall DA, Willison DJ, Grootendorst P, LeLorier J, Maclure M, Kulin NA, et al. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada. Health Policy 2007;84(1):1-13.
78. Motheral BR, Henderson R. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. The American Journal of Managed Care 1999;5(11):1383-94.
79. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Medical Care 2001;39(12):1293-304.
80. Mott DA, Thorpe JM, Thorpe CT, Kreling DH, Gadkari AS. Effects of Medicare Part D on drug affordability and use: are seniors with prior high out-of-pocket drug spending affected more?. Research in Social and Administrative Pharmacy 2010;6(2):90-9.
81. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. Journal of Managed Care Pharmacy 2003;9(2):123-33.
82. Nair KV, Frech-Tamas F, Jan S, Wolfe P, Allen RR, Saseen JJ. Comparing pre-gap and gap behaviors for medicare beneficiaries in a medicare managed care plan. Journal of Health Care Finance 2011;38(2):38-53.
83. Niteesh K. Choudhry. A Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies. Clinical Trials 2012.
84. O'Brien B. The effect of patient charges on the utilisation of prescription medicines. Journal of Health Economics 1989;8(1):109-32.
85. O'Reilly DJ, Goeree RA, Tarride JE, James C, Parfrey PS. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06. The Canadian Journal of Clinical Pharmacology 2009;16(2):e346-59.
86. Palmer LA, Fowler R, Shi N, Dastani H, Abouzaid S, Kim E. Impact of patient cost-sharing arrangements for disease modifying therapies on treatment compliance among patients with multiple sclerosis in the United States. Value in Health 2011;14(7):A328-9.
87. Pettersson B, Hoffmann M, Wändell P, Levin LÅ. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 2012;104(1):84-91.
88. Pettersson B, Hoffmann M, Andersson D, Wändell P, Levin LÅ. Utilization and costs of glucose lowering therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 2012;108(2-3):207-15.
89. Phillips VL, Atherly A. Prescription drug costs for dually eligible people in a medicaid home- and community-based services program. Journal of the American Geriatrics Society 2002;50(7):1283-8.
90. Puig-Junoy J, Garcia-Gomez P, Casado-Marin D. Free medicines thanks to retirement: moral hazard and hospitalization offsets in an NHS. Tinbergen Institute Discussion Paper 2011;108(3):1-31.
91. Raebel MA, Delate T, Ellis JL, Bayliss EA. Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D. Medical Care 2008;46(10):1116-22.
92. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered prescription copayments on the use of preferred brand medications. Medical Care 2003;41(3):398-406.
93. Sawyer DO. Pharmaceutical reimbursement and drug cost control: the MAC experience in Maryland. Inquiry 20;1(1983):76-87.
94. Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ 2004;328(7439):560.
95. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. American Journal of Managed Care 2007;13(8):445-52.
96. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 2007;115(16):2128-35.
97. Stroupe KT, Smith BM, Lee TA, Tarlov E, Durazo-Arvizu R, Huo Z, et al. Effect of increased copayments on pharmacy use in the Department of Veterans Affairs. Medical Care 2007;45(11):1090-7.
98. Subramanian S. Impact of medicaid copayments on patients with cancer: lessons for Medicaid expansion under health reform. Medical Care 2011;49(9):842-7.
99. Sun SX, Lee KY. The Medicare Part D doughnut hole: effect on pharmacy utilization. Managed Care Interface 2007;20(9):51-5, 59.
100. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. American Journal of Managed Care 2006;12(11):678-83.
101. Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA 2004;292(8):952-60.
102. Walberg MP, Patel RA, Amaral MM. Analysis of national annual variation in total patient out-of-pocket Medicare Part D stand-alone prescription drug plan costs from 2007 to 2008. Journal of Medical Economics 2008;11(4):625-37.
103. West DS, Johnson JT, Hong SH. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. Journal of Managed Care Pharmacy 2006;12(1):25-32.
104. White C, Sepulveda B, Doyle JJ. Medicare Part D's effect on prescribing volume: average monthly utilization of selected high use drugs in the protected classes by different specialties. Value in Health 2009;12(3):A95.
105. Yang Z, Norton EC. How much would a medicare prescription drug benefit cost? Offsets in Medicare part A cost by increased drug use. Journal of Pharmaceutical Finance, Economics and Policy 2007;15(2):97-119.
106. Ye X, Gross CR, Schommer J, Cline R, St Peter WL. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clinical Therapeutics 2007;29(12):2748-57.
107. Zeber JE, Grazier KL, Valenstein M, Blow FC, Lantz PM. Effect of a medication copayment increase in veterans with schizophrenia. American Journal of Managed Care 2007;13(6 Pt 2):335-46.
108. Zhang Y, Donohue JM, Newhouse JP, Lave JR. Trends. The effects of the coverage gap on drug spending: a closer look at Medicare part D. Health Affairs 2009;28(2):w317-25.
109. Zhang Y, Donohue JM, Lave JR, Gellad WF. The impact of Medicare part D on medication treatment of hypertension. Health Services Research 2011;46(1 Pt 1):185-98.
110. Zivin K, Madden JM, Graves AJ, Zhang F, Soumerai SB. Cost-related medication nonadherence among beneficiaries with depression following Medicare Part D. The American Journal of Geriatric Psychiatry 2009;17(12):1068-76.
111. Abraham C, Habiyaremye N, Neal J. Impact of a focused zero-dollar generic copayment program on adherence and compliance in a large managed care population. Academy of Managed Care Pharmacy 2009;15(7):586.
112. Almarsdottir AB, Morgall JM, Grimsson A. Cost containment of pharmaceutical use in Iceland: the impact of liberalization and user charges. Journal of Health Services Research & Policy 2000;5(2):109-13.
113. Banahan BFI, Datar M, Mendonca CM, Shahpurwala Z, Bentley JP, Phillips AL, et al. The effect of the Medicare part d coverage gap and out-of-pocket burden on the use of disease modifying drugs to treat multiple sclerosis. Value in Health 2011;14(3):A211.
114. Bennett S. The impact of the increase in user fees: a preliminary investigation. Lesotho Epidemiological Bulletin 1989;4(3):29-37.
115. Byrne DJ, Gertler PJ. An analysis of the impact of user fees on outpatient utilization in Lesotho. Not found 1990.
116. Cifaldi MA. The effect of having prescription drug coverage on health care expenditures by the noninstitutionalized, not disabled, Medicare population. Columbia, Missouri: Bloch School of Business and Public Administration and Department of Economics, University of Missouri; 2003.
117. Collins D, Quick JD, Musau SN, Kraushaar D, Hussein IM. The fall and rise of cost sharing in Kenya: the impact of phased implementation. Health Policy and Planning 1996;11(1):52-63.
118. Cubanski J. Three Studies on Policies to Reduce Medicare Drug Spending. Cambridge, Massachusetts: Harvard University; July 2004.
119. D'Souza AO, Rahnama R, Regan TS, Common B, Burch S. The H-E-B value-based health management program: impact on asthma medication adherence and healthcare cost. American Health and Drug Benefits 2010;3(6):394-402.
120. Damiani G, Federico B, Silvestrini G, Bianchi CB, Anselmi A, Iodice L, et al. Impact of regional copayment policy on selective serotonin reuptake inhibitor (SSRI) consumption and expenditure in Italy. European Journal of Clinical Pharmacology 2013;69(4):957-63.
121. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009;119(3):390-7.
122. Farley J. Medicaid prescription copayment policies and mental health outcomes in schizophrenia. Journal of the American Pharmacists Association 2010;50(2):256.
123. Fryatt RJ, Crowley SP, Gurung YB. Community financing of drug supplies in rural Nepal: evaluating a "fee per item" drug scheme. Health Policy and Planning 1994;9(2):193-203.
124. Gorsh B, Kim Y, Prasla K, Tabor T, Chaddick J, Godley PJ. Clinical and economic evaluation of a diabetes medication management program: 2 year program update. Value in Health 2011;14(3):A101.
125. Hsu J, Price M, Fung V. Prescription drug formularies and coverage: does a drug by any other name smell as sweet?. Value in Health 2009;12(7):A223.
126. Jonasson C, Jorgensen E, Tvete IF, Hatlebakk JG. Changes in prescriptions dispensed for proton pump inhibitors (PPIs) following new restrictions on reimbursement - A nationwide Norwegian prescription database study. Value in Health 2009;12(3):A58.
127. Joyce GF, Goldman DP, Vogt WB, Sun E, Jena AB. Medicare Part D after 2 years. American Journal of Managed Care 2009;15(8):536-44.
128. Khanna R, Dharmarajan SH, Null KD, Bentley JP, Pace PF, Banahan BF. Implementation of a state Medicaid prescription cap policy: is there an impact on beneficiaries' medical services utilization and costs?. Value in Health 2011;14(3):A111.
129. Kim YA, Smithline N, Serxner S, Yokoyama G. Impact of reduced copayments on medication adherence: Dx-Rx pairing program outcomes. Value in Health 2009;7:A242.
130. Kimmel SE, Troxel AB, Long J, Ibrahim S, Appleby D, Smith JO, et al. A randomized controlled trial of copayment reductions for blood pressure medication: the CHORD trial. Pharmacoepidemiology and Drug Safety 2009;18(Suppl 1):S134.
131. Landon BE, Rosenthal MB, Normand SL, Spettell C, Lessler A, Underwood HR, et al. Incentive formularies and changes in prescription drug spending. The American Journal of Managed Care 2007;13(6 Pt 2):360-9.
132. Lee YC, Yang MC, Huang YT, Liu CH, Chen SB. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoeconomics 2006;24(9):891-902.
133. Lee IH, Bloor K, Hewitt C, Maynard A. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea. Health Policy 2012;104(1):40-9.
134. Liu SZ, Romeis JC. Changes in drug utilization following the outpatient prescription drug cost-sharing program - Evidence from Taiwan's elderly. Health Policy 2004;68(3):277-87.
135. Liu FX, Alexander GC, Crawford SY, Pickard AS, Hedeker D, Walton SM. The impact of Medicare part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility. Health Services Research 2011;46(4):1104-23.
136. Sasso AT, Lurie IZ, Lee JU, Lindrooth RC. The effects of expanded mental health benefits on treatment costs. The Journal of Mental Health Policy and Economics 2006;9(1):25-33.
137. Maciejewski M, Wansink D, Farley J. Turning the tide? Medication adherence after copayment reductions. Society of General Internal Medicine Annual Meeting 2010 Apr 29.
138. Mahabaleshwarkar R, Banahan BFI. Effect of Medicare part D coverage GAP on medication consumption behaviors: case of oral anti-diabetic medications. Value in Health 2011;14(3):A102.
139. Martin BC, McMillan JA. The impact of implementing a more restrictive prescription limit on Medicaid recipients. Effects on cost, therapy, and out-of-pocket expenditures. Medical Care 1996;34:686-701.
140. Morgan S, Yan L. Income-based drug coverage in British Columbia: the impact on private and public expenditures. Health Policy 2006;2(2):e129-53.
141. Reiss SK, Ross-Degnan D, Zhang F, Soumerai SB, Zaslavsky AM, Wharam JF. Effect of switching to a high-deductible health plan on use of chronic medications. Health Services Research 2011;46(5):1382-401.
142. Rodin HA, Heaton AH, Wilson AR, Garrett NA, Plocher DW. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit. American Journal of Managed Care 2009;15(12):881-8.
143. Setoguchi S, Patrick AR, Dormuth C, Maclure M, Claire CF, Glynn RJ, et al. Differential effects of drug cost sharing policies on adherence to angiotensin blockers in patients with and without heart failure. Pharmacoepidemiology and Drug Safety 2009;18:S174.
144. Teixeira I, Mendes Z. Assessment of pharmaceutical expenditure trends in Portugal - pricing and reimbursement policy. Value in Health 2010;13(7):A419.
145. Teixeira I, Mendes Z. Assessment of pharmaceutical expenditure trends in Portugal - pricing and reimbursement policy. Value in Health 2010;13(7):A419.
146. Thengilsdttir G, Bjrnsdttir I, Almarsdttir AB. Incidence of statin use before and after restricting reimbursement in Iceland. Pharmacoepidemiology and Drug Safety 2010;19:S237.
147. Thompson M, Sedani T, Blak BT, Hards M. Impact of free prescriptions in wales on prescribing - a thin database study. Value in Health 2011;14(3):A13.
148. Wang PS, Patrick AR, Dormuth C, Maclure M, Avorn J, Canning CF, et al. Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants. Journal of Mental Health Policy and Economics 2010;13(1):37-44.
149. Wang CC, Wei D, Farley J. Impact of monthly prescription cap on medication persistency among patients with diabetes, hypertension, or hyperlipidemia. Value in Health 2011;14(3):A3.
150. Winkelmann R. Co-payments for prescription drugs and the demand for doctor visits - Evidence from a natural experiment. Health Economics 2004;13(11):1081-9.
151. Zeber JE, Copeland LA, Miller AL, Valenstein M, Leykum LI. A cost-benefit analysis of higher medication copayments in veterans with schizophrenia. Value in Health 2008;11(3):A115.
152. Zhang Y, Lee BY, Donohue JM. Ambulatory antibiotic use and prescription drug coverage in older adults. Archives of Internal Medicine 2010;170(15):1308-14.
153. Zhang Y, Lave JR, Donohue JM, Fischer MA, Chernew ME, Newhouse JP. The impact of Medicare part D on medication adherence among older adults enrolled in Medicare-advantage products. Medical Care 2010;48(5):409-17.
154. Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C, Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD005979]
155. Aaserud M, Dahlgren AT, Sturm H, Kösters JP, Hill S, Furberg CD, et al. Pharmaceutical policies: effects on rational drug use. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD004397.pub2]
156. Adams AS, Soumerai S, Ross-Degnan D. The case for a medicare drug coverage benefit: a critical review of the empirical evidence. Annual Review of Public Health 2001;22:49-61.
157. Baji P, Boncz I, Jenei G, Gulácsi L. Comparing cost-sharing practices for pharmaceuticals and health care services among four central European countries. Society and Economy 2012;34:221-40.
158. Baker D, Zipperer B. The Impact of the Medicare Drug Benefit on Health Care Spending by Older Households. Washington, DC: Center for Economic and Policy Research, 2008.
159. Dewa CS, Hoch JS. Fixed and flexible formularies as cost-control mechanisms. Expert Review of Pharmacoeconomics and Outcomes Research 2003;3(3):303-15.
160. Domino ME, Salkever DS. Price elasticity and pharmaceutical selection: the influence of managed care. Health Economics 2003;12(7):565-86.
161. Effective Practice, Organisation of Care (EPOC). What study designs should be included in an EPOC review and what should they be called?. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: http://epoc.cochrane.org/epoc-specific-resources-review-authors 2013, issue accessed 13 November 2013.
162. Effective Practice, Organisation of Care (EPOC). Suggested risk of bias criteria for EPOC reviews. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: http://epoc.cochrane.org/epoc-specific-resources-review-authors 2013, issue accessed 13 November 2013.
163. Effective Practice, Organisation of Care (EPOC). Interrupted time series (ITS) analyses. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: http://epoc.cochrane.org/epoc-specific-resources-review-authors 2013, issue accessed 13 November 2013.
164. Effective Practice, Organisation of Care (EPOC). EPOC worksheets for preparing a Summary of Findings (SoF) table using GRADE. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: http://epoc.cochrane.org/epoc-specific-resources-review-authors 2013.
165. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21(2):89-103.
166. Freemantle N, Bloor K. Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients. BMJ 1996;312(7044):1469-71.
167. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. American Journal of Managed Care 2003;11(11):730-40.
168. Ginsburg PB, Manheim LM. Insurance, co-payment, and health services utilization: a critical review. Journal of Economics and Business 1973;25:142-53.
169. Gleason PP, Solberg CL, Brelje TV, Hartwig SC, Wadd W. Assessment of a retrospective drug utilization review alert letter program. Journal of Clinical Outcomes Management 2004;11:150-4.
170. Gross DJ, Ratner J, Perez J, Glavin SL. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom. Health Care Financing Review 1994;15(3):127-40.
171. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ, the GRADE Working Group. What is 'quality of evidence' and why is it important to clinicians?. BMJ 2008;336:995-8.
172. Haaijer-Ruskamp FM. Experience with patient charges. International Journal of Risk & Safety in Medicine 2002;15:93-6.
173. Harten C, Ballantyne P. The impact of cost-sharing within Canadian provincial drug benefit programs: a review. Journal of Pharmaceutical Finance, Economics & Policy 2004;13:35-53.
174. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. www.cochrane-handbook.org. The Cochrane Collaboration [updated March 2011], 2011.
175. Huttin C. The use of prescription charges. [Review]. Health Policy 1994;27:53-7.
176. Jang R. Medicaid formularies: a critical review of the literature. Journal of Pharmaceutical Marketing & Management 1988;2(3):39-61.
177. Johnston M. The price elasticity of demand for pharmaceuticals. Economics and Health: Proceedings of the Twelfth Australian Conference. 1990.
178. Levy RA. Prescription cost sharing: economic and health impacts, and implications for health policy. Pharmacoeconomics 1992;2(3):219-37.
179. Lexchin J, Grootendorst P. The effects of prescription drug user fees on health services use and health status: a review of the evidence. Working Paper, Department of Clinical and Epidemiology and Biostatistics, McMaster University, Ontario, Canada. Ontario, Canada, 2002.
180. Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. International Journal of Health Services 2004;34:101-22.
181. Lyles A, Palumbo FB. The effect of managed care on prescription drug costs and benefits. [Review]. Pharmacoeconomics 1999;15(2):129-40.
182. Mossialos E, Walley T, Mrazek M. Regulating pharmaceuticals in Europe: an overview. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. Maidenhead, UK: Open University Press, 2004:1-37.
183. Nair KV, Valuck RJ. Impact of three-tier pharmacy benefit structures on consumer attitudes, pharmacy, medical utilization and costs: a critical review. Disease Management & Health Outcomes 2004;12:81-92.
184. Narine L, Senathirajah M. Pharmaceutical cost containment policies: intended and unintended impacts. Department of Health Administration, Faculty of Medicine. University of Toronto, 1997.
185. Noyce PR, Huttin C, Atella V, Brenner G, Haaijer-Ruskamp FM, Hedvall M, et al. The cost of prescription medicines to patients. Health Policy 2000;52(2):129-45.
186. O'Grady KF, Manning WG, Newhouse JP, Brook RH. The impact of cost sharing on emergency department use. New England Journal of Medicine 1985;313:484-90.
187. Polinski JM, Kilabuk E, Schneeweiss S, Brennan T, Shrank WH. Changes in drug use and out-of-pocket costs associated with medicare part D implementation: a systematic review. Journal of the American Geriatrics Society 2010;58:1764-79.
188. Polinski JM, Donohue JM, Kilabuk E, Shrank WH. Medicare Part D's effect on the under- and overuse of medications: a systematic review. Journal of the American Geriatrics Society 2011;59:1922-33.
189. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series design in health technology assessment: lessons from two systematic reviews of behavior change strategies. International Journal of Technology Assessment in Health Care 2003;19(4):612-23.
190. Reeder CE, Lingle EW, Schulz RM, Mauch R, Nightengale BS, Pedersen CA, et al. Economic impact of cost-containment strategies in third party programmes in the US (Part 1). Pharmacoeconomics 1993;4(2):92-103.
191. Reutzel T. The nature and consequences of policies intended to contain costs in outpatient drug insurance programs. Clinical Therapeutics 1993;15(4):752-64.
192. Rice T, Morrison KR. Patient cost sharing for medical services: a review of the literature and implications for health care reform. Medical Care Review 1994;51(3):235-87.
193. Rice T, Matsuoka KY. The impact of cost-sharing on appropriate utilization and health status: a review of the literature on seniors. Medical Care Research and Review 2004;61:415-52.
194. Sinnott S-J, Buckley C, O'Riordan D, Bradley C, Whelton H. The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations: a systematic review and meta-analysis. PLoS ONE 2013;8(5):e64914.
195. Smith DG, Kirking DM. Impact of consumer fees on drug utilisation. Pharmacoeconomics 1992;2(4):335-42.
196. Soumerai S, Ross-Degnan D. Experience of state drug benefit programs. Health Affairs 1990;9(3):36-54.
197. Thomson S, Mossialos E. Influencing demand for drugs through cost sharing. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. Maidenhead, UK: Open University Press, 2004:227-44.
198. WHO (World Health Organization). Medicines and Rational Use. Fact sheet. Geneva: World Health Organization, 2010. [: http://www.who.int/mediacentre/factsheets/fs338/en/]
199. Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD007017]